Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cariprazine dose-reduction randomized-withdrawal trial for relapse prevention in schizophrenia
2017-000818-34Phase 3Completed
- Sponsor
- Allergan
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Cariprazine 4.5 mg/day with Placebo (2 arms). Primary endpoint: Time to first relapse during double-blind treatment. Started Jul 2019; status: completed.
02
Drugs
cariprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2017-000818-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000818-34.